Phoenix Power Players Trade Blows With CVS Over Soaring Drug Bills

Arizona’s fight over how to tame soaring health and prescription costs jumped from the Capitol to the conference room Friday, as business and political heavyweights traded shots with CVS over who should pay and who should save.

At a Phoenix Business Journal "Table of Experts" panel, the conversation started politely enough, with calls for collaboration on lowering premiums and out-of-pocket drug prices. It did not stay polite for long. The room quickly split over whether tax cuts, new rules for pharmacy benefit managers or old-fashioned market pressure offer the best path to relief.

The panel, moderated by Phoenix Business Journal market president Ray Schey, featured House Speaker Steve Montenegro, longtime government-relations figure Jaime Molera and a senior CVS Caremark executive, among others, according to the Phoenix Business Journal. Participants warned that well-intended fixes could backfire, triggering higher premiums or shrinking pharmacy networks instead of real savings.

Lawmakers Lean On Tax Conformity As An Affordability Play

House leaders on the panel pushed tax conformity as their big lever. By aligning Arizona’s tax code with recent federal changes, they argued, the state could unlock what various estimates peg at roughly $1.1 billion in relief over several years for households and small businesses.

Coverage in the AZ Mirror shows that fight over conformity has become a central flashpoint this session, setting the political backdrop for any affordability talk. The panel’s tax-cut pitch landed squarely in that larger showdown between legislative Republicans and the governor.

Small-Business Groups Sound Alarm On Possible Premium Hikes

On the business side of the table, the message was blunt: health costs are already the top headache for many small employers, and some new regulations could make that migraine worse.

The National Federation of Independent Business in Arizona lists health-care affordability among its members’ leading concerns. Bills that target how pharmacy benefit managers pay pharmacies, including HB 2196 now moving through the Legislature, are adding to the anxiety. The bill text and activity are posted on LegiScan, where committee actions are logged.

NFIB representatives have been clear about what their members want: predictability and lower costs, not surprise premium spikes tied to well-meaning but poorly calibrated rule changes.

CVS Touts Its Muscle, Warns Of Hits To Local Pharmacy Network

CVS executives leaned heavily on their scale argument. The company, they told the crowd, uses its size to negotiate lower prices and deliver services at a volume no small operator can match. At the same time, they warned that certain proposals aimed at PBM ownership structures and reimbursement rules could make it tougher to keep some Arizona locations viable, and could ultimately force closures.

Corporate filings and disclosures outline the breadth of that footprint, with state store counts approaching 200 locations when in-store pharmacies are included and PBM operations moving prescriptions at very large scale. For more detail on the company’s reach, see the Phoenix Business Journal coverage, the CVS 10-K on the SEC site and public statements in a CVS Health release describing Aetna and CVS Health market reach.

What To Watch Next

At the Capitol, lawmakers will keep juggling tax and PBM proposals as bills advance through committees and, potentially, to the governor’s desk. Small tweaks in reimbursement language or in the size and shape of any tax-conformity package could reshuffle who benefits and who ends up footing the bill.

Observers following PBM and tax measures can track bill texts and calendars at the Arizona Legislature and through tools like LegiScan, where measures such as SB 1545 and HB 2196 are listed as the session unfolds.

For now, the panel made one thing very clear: everyone on stage agrees that health and drug costs need to come down. They just do not agree on whether the fix should come from the tax code, tougher PBM rules or market forces. That argument is not ending anytime soon, and it will keep playing out in hearing rooms, boardrooms and pharmacy aisles across the Valley.